Literature DB >> 11083637

Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.

G Sindelar1, X Zhao, A Liew, Y Dong, T Lu, J Zhou, J Domagala, K Drlica.   

Abstract

Mutant prevention concentration (MPC) has been proposed as a new measure of antibiotic potency by which the ability to restrict selection of resistant mutants is evaluated. To determine whether MPC provides potency information unavailable from the more customary measurement of the MIC, 18 fluoroquinolones were examined for their ability to block the growth of Mycobacterium smegmatis and to select resistant mutants from wild-type populations. Both MPC and MIC were affected by changes in the moiety at the fluoroquinolone C-8 position and in alkyl groups attached to the C-7 piperazinyl ring. When eight resistant mutants, altered in the gyrase A protein, were tested with fluoroquinolones having either a methoxy or a hydrogen at the C-8 position, the MIC for the most resistant mutant correlated better with the MPC than did the MIC for wild-type cells. For C-8-fluorine derivatives, which were generally less active than the C-8-methoxy compounds but which were more active than C-8-hydrogen derivatives, the MICs for both the mutant and the wild type correlated well with the MPCs. Thus, measurement of the MICs for wild-type cells can reflect the ability of a quinolone to restrict the selection of resistance, but often it does not. With the present series of compounds, the most potent contained a C-8-methoxy and a small group attached to the C-7 ring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083637      PMCID: PMC90202          DOI: 10.1128/AAC.44.12.3337-3343.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.

Authors:  J Zhou; Y Dong; X Zhao; S Lee; A Amin; S Ramaswamy; J Domagala; J M Musser; K Drlica
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

Review 3.  Genetic systems for mycobacteria.

Authors:  W R Jacobs; G V Kalpana; J D Cirillo; L Pascopella; S B Snapper; R A Udani; W Jones; R G Barletta; B R Bloom
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  Crystal structure of the breakage-reunion domain of DNA gyrase.

Authors:  J H Morais Cabral; A P Jackson; C V Smith; N Shikotra; A Maxwell; R C Liddington
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.

Authors:  G Klopman; D Fercu; T E Renau; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.

Authors:  E Cambau; F Bordon; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family.

Authors:  P J Bifani; B B Plikaytis; V Kapur; K Stockbauer; X Pan; M L Lutfey; S L Moghazeh; W Eisner; T M Daniel; M H Kaplan; J T Crawford; J M Musser; B N Kreiswirth
Journal:  JAMA       Date:  1996-02-14       Impact factor: 56.272

9.  Emergence of fluoroquinolone-resistant tuberculosis in New York City.

Authors:  E A Sullivan; B N Kreiswirth; L Palumbo; V Kapur; J M Musser; A Ebrahimzadeh; T R Frieden
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  32 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region.

Authors:  S M Friedman; T Lu; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 5.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

6.  Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; George N Konstantinides; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Low correlation between MIC and mutant prevention concentration.

Authors:  Karl Drlica; Xilin Zhao; Joseph M Blondeau; Christine Hesje
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

8.  Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus.

Authors:  Inshad Ali Khan; Zahid Mehmood Mirza; Ashwani Kumar; Vijeshwar Verma; Ghulam Nabi Qazi
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 9.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

10.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.